Filed by PhotoMedex, Inc.
      Pursuant to Rule 425 under the Securities Exchange Act of 1933, as amended
                              Subject Company: Surgical Laser Technologies, Inc.
                                                   Commission File No. 000-17919
                                          Press Release dated September 26, 2002

         On September 26, 2002, PhotoMedex, Inc., a Delaware corporation, issued
the following press release:

                                     * * * *

Contact:

PHOTOMEDEX, INC.                               SURGICAL LASER TECHNOLOGIES, INC.
Dennis McGrath                                 Davis Woodward
Chief Financial Officer                        Chief Financial Officer
Telephone:  (610) 971-9292                     Telephone (215) 619-3278
Email:  mgensel@photomedex.com                 dwoodward@slti.com

            PHOTOMEDEX AGREES TO ACQUIRE SURGICAL LASER TECHNOLOGIES

         RADNOR, Pa.--(BUSINESS WIRE)--September 26, 2002--PhotoMedex, Inc.
(Nasdaq: PHMD) and Surgical Laser Technologies, Inc. (Nasdaq: SLTI) today
announced that on September 25, 2002, they entered into a definitive merger
agreement pursuant to which PhotoMedex will acquire Surgical Laser Technologies
(SLT).

         SLT employs a similar business model to PhotoMedex, charging a per
procedure fee, thereby limiting the initial outlay for capital expenditure to
the doctor's office, hospital or surgi-center while ensuring continued revenue
flow to the company. SLT offers a wide range of laser services, including
Urology, Gynecology, Orthopedics, and General Surgery. In addition to the
utilization of such lasers as the Holmium, Diode, YAG Contact Laser, and CO2
Laser, SLT is a world wide leader in the development, manufacturing and
marketing of healthcare lasers and their disposables.

         Jeff O'Donnell, President and CEO, commented, "PhotoMedex has been
focused on Dermatological applications for its XTRAC(TM) laser system. Now, as
it approaches an environment of full reimbursement, PhotoMedex looks to other
opportunities in healthcare with companies that share our vision for the
business model of the future. We have found this in SLT and believe that by
combining our resources, vision and technology, we will own the capabilities of
providing capital equipment, clinical specialists and disposables; thereby
providing the opportunity for the medical facility to contract with us to
effectively and efficiently outsource comprehensive services in many different
medical specialties. This value proposition will increase profits for the
hospital and simplify the procedural logistics. I look forward to expanding our
verticals in laser procedures through the consolidation of our companies,
thereby maximizing the value to our customers."

         Commenting on the business combination, Michael R. Stewart, SLT's
President and CEO stated, "We are very pleased to be joining forces with
PhotoMedex and are excited about the opportunities that the combination
presents. Each Company's products and services are natural extensions of the
other. We have a shared vision for the future and believe that, with our



collective offerings, we are well-positioned to continue the expansion of our
contract services approach in the marketplace. The management and Board of SLT
have focused on restructuring the Company, in an effort to increase stockholder
value. We believe that this combination positions the SLT stockholders to better
realize on those efforts and will be in their best interest."

         Under the terms of the proposed merger, SLT's stockholders will receive
1.12 shares of newly issued PhotoMedex common stock in exchange for each share
of SLT common stock they hold. As a result of the merger transaction, PhotoMedex
expects to issue a total of approximately 2.6 million shares of common stock and
assume certain outstanding common stock purchase warrants of SLT. On a pro forma
basis, assuming that all SLT stockholders exchange PhotoMedex shares for their
SLT shares, SLT's stockholders would own approximately 9.2% of the combined
company's capital stock without giving effect to the exercise of any SLT options
before closing. Based on the stock price of PhotoMedex at the close of business
on September 24, 2002, this would result in a purchase price of $1.34 per share
of SLT common stock.

         The merger is subject to approval by the stockholders of SLT. The
directors and officers of SLT, who collectively own approximately 15% of the
outstanding SLT common stock, have agreed to vote all of their shares of SLT
common stock in favor of approval and adoption of the proposed merger
transaction. The merger is also subject to other customary closing conditions,
and is expected to close in the fourth quarter of 2002.

         A conference call will be held on Thursday, September 26, at 2:00 p.m.
Eastern Daylight Time, during which, Jeff O'Donnell, the President and CEO of
PhotoMedex, and Michael R. Stewart, the President and CEO of Surgical Laser
Technologies, Inc., will discuss today's announcement.

         To participate in the conference call, dial 800.395.0708 (and
confirmation code # 658765) approximately 5 to 10 minutes prior to the scheduled
start time. If you are unable to participate, a digital replay of the call will
be available from Thursday, September 26 at 4:00 p.m. EDT until midnight on
Thursday, October 9, by dialing 888.203.1112 and using confirmation code #
658765.

         The live broadcast of PhotoMedex, Inc.'s conference call will be
available online by going to www.photomedex.com and clicking on the link to
Investor Relations, and at www.streetevents.com. The online replay will be
available shortly after the call at those sites.

About PhotoMedex:

         PhotoMedex is engaged in the development of proprietary excimer laser
and fiber optic systems and techniques directed toward dermatological
applications, with FDA approval to market the XTRAC(TM) laser system for the
treatment of psoriasis, vitiligo, eczema and Leukoderma.

         PhotoMedex's excimer laser system generating 308-nm UV-B radiation is
the first FDA-approved laser treatment for psoriasis, which is the second most
common skin disorder in the U.S. The National Psoriasis Foundation estimates
that psoriasis afflicts more than 7 million Americans and that between 150,000
and 260,000 new cases are diagnosed each year. The XTRAC(TM) laser system is
also the first FDA approved excimer laser system to treat vitiligo, a skin
disease that, according to the National Vitiligo Foundation, afflicts
approximately 1 to 2% of Americans, and eczema, a skin disease that is estimated
to afflict 15 million Americans.

                                       2


About Surgical Laser Technologies:

         Surgical Laser Technologies is a worldwide leader in the development,
manufacture, and marketing of lasers and disposable Contact Laser(TM) Delivery
Systems that can be used in virtually all general and specialty surgical
procedures. SLT markets proprietary Contact Laser Delivery Systems that provide
the surgeon with precise and controlled cutting, vaporization and coagulation of
tissue.

                              SAFE HARBOR STATEMENT

         This press release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. These statements are based on managements' current
expectations and beliefs and are subject to a number of factors and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. The forward-looking statements
contained in this release include statements about future financial and
operating results and the proposed acquisition of Surgical Laser Technologies,
Inc. ("SLT") by PhotoMedex, Inc. ("PhotoMedex").

         The following factors, among others, could cause actual results to
differ materially from those described in the forward-looking statements: the
risk that SLT's business will not be integrated successfully with that of
PhotoMedex, costs related to the merger, failure of the SLT stockholders to
approve the merger, risks relating to technology and product development, market
acceptance, government regulation and regulatory approval processes,
intellectual property rights and litigation, dependence on strategic partners,
ability to obtain financing, competitive products and other risks identified in
PhotoMedex's and SLT's filings with the SEC. PhotoMedex and SLT are under no
obligation to (and expressly disclaim any such obligation to) update or alter
these forward-looking statements, whether as a result of new information, future
events or otherwise.

         In connection with the proposed merger, PhotoMedex will file with the
Securities and Exchange Commission ("SEC") a registration statement on Form S-4.
The registration statement will include a proxy statement of SLT for a meeting
of its stockholders to consider and vote upon the proposed merger. The
registration statement will also serve as a prospectus of PhotoMedex with
respect to the shares of PhotoMedex to be distributed to stockholders of SLT in
the proposed transaction. PhotoMedex and SLT will file the proxy
statement/prospectus with the SEC as soon as practicable. INVESTORS AND SECURITY
HOLDERS ARE ADVISED TO CAREFULLY READ THE PROXY STATEMENT/PROSPECTUS REGARDING
THE PROPOSED MERGER TRANSACTION, WHEN IT BECOMES AVAILABLE, BECAUSE IT WILL
CONTAIN IMPORTANT INFORMATION ABOUT PHOTOMEDEX, SLT, THE MERGER AND RELATED
MATTERS.

         In addition to the registration statement and proxy
statement/prospectus, both PhotoMedex and SLT file annual, quarterly and other
reports, proxy statements, registration statements and other information with
the SEC. You may read and copy any reports, statement or other information filed
by PhotoMedex or SLT at the SEC's public reference rooms at 450 Fifth Street,
N.W., Washington, D.C. 20549 or at any of the SEC's other public reference rooms
in New York, New York and Chicago, Illinois. Please call the SEC at

                                       3


1-800-SEC-0330 for further information on the public reference rooms. Investors
and security holders may also obtain a free copy of the proxy
statement/prospectus (when it is available) and other documents filed by the
companies at the SEC's web site at http://www.sec.gov.

         PhotoMedex, SLT, their respective officers and directors and certain
other members of management or employees may be deemed to be participants in the
solicitation of proxies from stockholders of SLT with respect to the
transactions contemplated by the merger agreement. A description of any
interests that PhotoMedex's or SLT's directors and executive officers have in
the proposed merger will be available in the proxy statement/prospectus.

         This press release is not an offer to purchase shares of SLT, nor is it
an offer to sell shares of PhotoMedex common stock, which may be issued in any
proposed merger with SLT. Any issuance of PhotoMedex common stock in any
proposed merger with SLT would have to be registered under the Securities Act of
1933, as amended, and such PhotoMedex common stock would be offered only by
means of a prospectus complying with such act.

                                       4